[1] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 2020 Dec 31;383(27):2603-15. https://doi.org/10.1056/NEJMoa2034577.
[2] Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. New England Journal of Medicine. 2021 Feb 24. https://doi.org/10.1056/NEJMoa2101765.
[3] Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants—clinical, public health, and vaccine implications. New England Journal of Medicine. 2021 May 13;384(19):1866-8. https://doi.org/10.1056/NEJMc2100362
[4] Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, Kornblum N. Seroconversion rates following COVID-19 vaccination amongst patients with cancer. Cancer Cell. 2021 Jun 5.https://doi.org/10.1016/j.ccell.2021.06.002
[5] Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales M, Ziv T, Shorer Arbel Y, Scarfo L, Joffe E. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood, The Journal of the American Society of Hematology. 2021 Jun 10;137(23):3165-73.https://doi.org/10.1182/blood.2021011568
[6] Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, Di Marco M, Kaklamani V, Dietrich PY, Taylor BS, Simand PF, Patel D. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021 Jun 18.https://doi.org/10.1016/j.ccell.2021.06.009
[7] Israel Ministry of health. COVID-19 in Israel - dashboard data. https://datadashboard.health.gov.il/COVID-19/general. Accessed August 25, 2021.
[8] Cohen D, Krauthammer SH, Wolf I, Even-Sapir E. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18 F] FDG PET-CT and relevance to study interpretation. European Journal of Nuclear Medicine and Molecular Imaging. 2021 Jun;48(6):1854-63.https://doi.org/10.1007/s00259-021-05314-2
[9] Eshet Y, Tau N, Alhoubani Y, Kanana N, Domachevsky L, Eifer M. Prevalence of Increased FDG PET/CT Axillary Lymph Node Uptake Beyond 6 Weeks after mRNA COVID-19 Vaccination. Radiology. 2021 Apr 27:210886.https://doi.org/10.1148/radiol.2021210886
[10] Skawran S, Gennari AG, Dittli M, Treyer V, Muehlematter UJ, Maurer A, Burger IA, Mader C, Messerli O, Grünig H, Gebhard C. [18F] FDG uptake of axillary lymph nodes after COVID-19 vaccination in oncological PET/CT: frequency, intensity, and potential clinical impact. European Radiology. 2021 Jun 22:1-9.https://doi.org/10.1007/s00330-021-08122-2
[11] Özütemiz C, Krystosek LA, Church AL, Chauhan A, Ellermann JM, Domingo-Musibay E, Steinberger D. Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncology Patients. Radiology. 2021 Feb 24:210275. https://doi.org/10.1148/radiol.2021210275.
[12] Bolton RC, Terán AK, Erba PA, Giammarile F. Medical imaging in times of pandemic: focus on the cornerstones of successful imaging.European Journal of Nuclear Medicine and Molecular Imaging. 2021 Jun;48(6):1724–25. https://doi.org/10.1007/s00259-021-05331-1
[13] Becker AS, Perez-Johnston R, Chikarmane SA, Chen MM, El Homsi M, Feigin KN, Gallagher KM, Hanna EY, Hicks M, Ilica AT, Mayer EL. Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel. Radiology. 2021 Feb 24:210436. https://doi.org/10.1148/radiol.2021210436.
[14] Cohen D, Krauthammer SH, Cohen YC, Perry C, Avivi I, Herishanu Y, Even-Sapir E. Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. European Journal of Nuclear Medicine and Molecular Imaging. 2021 May 8:1-0.https://doi.org/10.1007/s00259-021-05389-x
[15] Eifer M, Tau N, Alhoubani Y, Kanana N, Domachevsky L, Shams J, Keret N, Gorfine M, Eshet Y. Covid-19 mRNA Vaccination: Age and Immune Status and its Association with Axillary Lymph Node PET/CT Uptake. Journal of Nuclear Medicine. 2021 Apr 1.https://doi.org/10.2967/jnumed.121.262194
[16] Treglia G, Cuzzocrea M, Giovanella L, Elzi L, Muoio B. Prevalence and Significance of Hypermetabolic Lymph Nodes Detected by 2-[18F] FDG PET/CT after COVID-19 Vaccination: A Systematic Review and a Meta-Analysis. Pharmaceuticals. 2021 Aug;14(8):762.https://doi.org/10.3390/ph14080762
[17] Collier DA, Ferreira IA, Kotagiri P, Datir R, Lim E, Touizer E, Meng B, Abdullahi A, Elmer A, Kingston N, Graves B. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021 Jun 30:1-9.https://doi.org/10.1038/s41586-021-03739-1
[18] Pellini R, Venuti A, Pimpinelli F, Abril E, Blandino G, Campo F, Conti L, De Virgilio A, De Marco F, Di Domenico EG, Di Bella O. Obesity may hamper SARS-CoV-2 vaccine immunogenicity. medRxiv. 2021 Jan 1.https://doi.org/10.1101/2021.02.24.21251664
[19] Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, Tabib Y, Cohen YC, Benyamini N, Beyar-Katz O, Neaman M. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Advances. 2021 Aug 24;5(16):3053-61.https://doi.org/10.1182/bloodadvances.2021005094
[20] Abbas, A. K., Abbas, A. K., Lichtman, A. H., & Pillai, S. (2018). Cellular and molecular immunology. Elsevier.